VaccinationARISeNCT07236034

ARISe at UMass Chan

A study testing Exposure to source and message content in people with Vaccination and Vaccination Promotion, run by University of Massachusetts, Worcester at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts

Official record

Search all trials

Trial summary

Who is it for?: Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for: Vaccination, Vaccination Promotion
What is being tested?: Exposure to source and message content
Type of treatment: Lifestyle or therapy programme
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 700 participants
Where: 1 siteUnited States
Study dates: 1 Dec 2025to 30 Dec 2026
Phase: Interventional
Are there results?: Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
Healthy volunteers accepted
Adult, Older adult

Who may be able to join

Age 18+
Living in New England state (CT, MA, ME, NH, VT RI) in a zip code as defined by each individual state's definition of rural
Able to read and write in English
Access to an internet connected computer or laptop with a web-camera

Who cannot join

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Grace W Ryan, PhD, MPH contact

508-859-0179

grace.ryan1@umassmed.edu

United States1 site, 1 recruiting

University of Massachusetts Chan Medical School
Worcester, Massachusetts, 01605
Grace Assistant Professor, PhD, MPH, 508-859-0179, arise@umassmed.edu
Recruiting

Other trials in United States

About this study

Official title: ARISe at UMass Chan: Remote Eye Tracking Study of Vaccine Messaging in Rural Populations

The goal is to identify the most impactful strategies for capturing attention and enhancing effectiveness of vaccine promotion messages. This will be done using an online survey that employs remote eye-tracking and self report measures to evaluate response to sample vaccine promotion social media content in rural populations in New England. Participants will be randomly assigned into one of 14 conditions in a 2(source: expert vs. influencer) by 7 (themes: constructs from 7C Vaccine Framework) experiment and view sample messages and then answer questions about their attitudes and beliefs while being monitored for eye-tracking.

Conditions: Vaccination, Vaccination Promotion
Being tested: Exposure to source and message content
Keywords: Message perceptions, Vaccination, Immunization

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Exposure to source and message contentBehavioural
Within each arm, participants will be exposed to two messages each of which are delivered by the same source (peer or professional) and have message content related to one of the 7C Constructs.

Study groups in NCT07236034
Study group	Role	What they receive
Arm 1: Peer message, 7C Construct 1	Experimental	This arm will include messages with a "peer" influence as the source and the construct of "confidence" as the message. Receives: Behavioral: Exposure to source and message content
Arm 2: Professional source, 7C Construct 1	Experimental	This arm will include messages with a "professional" influencer as the source and the construct of "confidence" as the message. Receives: Behavioral: Exposure to source and message content
Arm 3: Peer message, 7C Construct 2	Experimental	This arm will include messages with a "peer" influence as the source and the construct of "complacency" as the message. Receives: Behavioral: Exposure to source and message content
Arm 4: Professional message, 7C Construct 2	Experimental	This arm will include messages with a "professional" influence as the source and the construct of "complacency" as the message. Receives: Behavioral: Exposure to source and message content
Arm 5: Peer message, 7C Construct 3	Experimental	This arm will include messages with a "peer" influence as the source and the construct of "constraints" as the message. Receives: Behavioral: Exposure to source and message content
Arm 6: Professional message, 7C Construct 3	Experimental	This arm will include messages with a "professional" influencer as the source and the construct of "constraints" as the message. Receives: Behavioral: Exposure to source and message content
Arm 7: Peer message, 7C Construct 4	Experimental	This arm will include messages with a "peer" influencer as the source and the construct of "calculation" as the message. Receives: Behavioral: Exposure to source and message content
Arm 8: Professional message, 7C Construct 4	Experimental	This arm will include messages with a "professional" influencer as the source and the construct of "calculation" as the message. Receives: Behavioral: Exposure to source and message content
Arm 9: Peer message, 7C Construct 5	Experimental	This arm will include messages with a "peer" influencer as the source and the construct of "collective responsibility" as the message. Receives: Behavioral: Exposure to source and message content
Arm 10: Professional message, 7C Construct 5	Experimental	This arm will include messages with a "professional" influencer as the source and the construct of "collective responsibility" as the message. Receives: Behavioral: Exposure to source and message content
Arm 11: Peer message; 7C Construct 6	Experimental	This arm will include messages with a "peer" influencer as the source and the construct of "compliance" as the message. Receives: Behavioral: Exposure to source and message content
Arm 12: Professional message, 7C Construct 6	Experimental	This arm will include messages with a "professional" influencer as the source and the construct of "compliance" as the message. Receives: Behavioral: Exposure to source and message content
Arm 13: Peer message, 7C Construct 7	Experimental	This arm will include messages with a "peer" influencer as the source and the construct of "conspiracy" as the message. Receives: Behavioral: Exposure to source and message content
Arm 14: Professional message, 7C Construct 7	Experimental	This arm will include messages with a "professional" influencer as the source and the construct of "conspiracy" as the message. Receives: Behavioral: Exposure to source and message content

What is being measured

The primary outcome is the main question the study is designed to answer.

Source credibility
Participants' perception of the credibility of the message source will be assessed using a 7-point Likert scale measured across four items. Participants will be asked to rate the following four items on this scale: To what extent do you believe the source of the message to be… (1=not at all, 7=very much so)
1. Fair
2. Accurate
3. Telling the whole story
4. Trustworthy
Unit of measure: Scale score 1-7, mean
Measured: Immediately after viewing each message
Perceived Message Effectiveness
Perceived message effectiveness will be measured using six items (worth remembering, grabs attention, powerful, informative, meaningful, convincing), each rated on a 7-point Likert scale. The outcome will be the mean of these six ratings for each participant, then averaged by experimental condition.
To what extent is… (1=not at all, 7=very much so)
1. The message worth remembering
2. The message grabs attention
3. This message powerful
4. This message informative
5. This message meaningful
6. This message convincing Unit of Measure: Scale score (1-7, mean across items)
Measured: Immediately after viewing each message
Visual attention
Visual attention, quantified as mean dwell time in milliseconds, will be measured using remote eye-tracking while participants view vaccine promotion messages. Dwell time will be calculated for pre-specified Areas of Interest (AOIs) during the message viewing period. Higher dwell times indicate greater visual attention to the AOIs.
Unit of measure: mean dwell time in milliseconds per message
Measured: During message viewing ( immediately post-randomization, prior to completion of post-message survey)
Message reactance
Reactance will be assessed using four items (irritated, angry, annoyed, aggravated), rated 0 ("None of this feeling") to 4 ("A great deal of this feeling"). The mean reactance score will be calculated for each participant.
How much did this message make you feel the following way? Response options: 0 (None of this feeling) to 4 (A great deal of this feeling).
1. Irritated
2. Angry
3. Annoyed
4. Aggravated
Unit of Measure: Scale score (0-4, mean across items)
Measured: Immediately after viewing each message
Information sharing intentions
Description: Assessed with 6 items regarding interpersonal and online sharing, rated 1 (Strongly disagree) to 5 (Strongly agree). The mean score across items will be reported per participant and per condition.
Rate with the following statements on a scale from 1 (Strongly disagree) to 5 (Strongly agree).
Interpersonal setting
1. I would be willing to share this information with others.
2. I would talk with others about this message.
3. I would point others in a direction where they could read this message. Online setting
4. I would be willing to post a link to this information on my social media.
5. I would like a social media post with this information.
6. I would share a social media post with this information.
Unit of Measure: Scale score (1-5, mean across items)
Measured: Immediately after viewing each message

Secondary outcomes (1)

Vaccine perceptions
Vaccine perceptions will be measured using an 8-item scale, administered pre- and post-message exposure. Items are rated from 1 (Strongly disagree/very negative) to 7 (Strongly agree/very positive). Higher scores indicate more positive vaccine perceptions. The outcome will be the mean change in score from pre- to post-exposure.
Unit of Measure: Scale score (1-7, mean change)
Measured: Assessed at baseline (prior to message exposure) and immediately post-intervention (after message exposure)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

1 Dec 202530 Dec 2026

First posted19 Nov 2025
Study start1 Dec 2025
Primary completion30 Sep 2026 (estimated)
Study completion30 Dec 2026 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for VaccinationStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Health services research
Allocation: Randomised
Intervention model: Factorial
Model description: Participants will be assigned to one of 14 conditions and view two messages within each.
Masking: Double blind
Who is masked: Participant, Investigator
Enrolment: 700 participants (estimated)

IDs, dates and publications

ClinicalTrials.gov ID: NCT07236034
Sponsor's protocol ID: STUDY00002075
Other IDs: 1U48DP006883-01
Acronym: ARISe
Status last verified: Jul 2026
First submitted: 1 Oct 2025
Last updated: 7 Jul 2026
Results posted: No
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: Yes: Per the data management plan, datasets and codebooks will be provided to individual researchers upon reasonable request.

Interested in taking part?

Grace W Ryan, PhD, MPH

508-859-0179

grace.ryan1@umassmed.edu

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See sites and contacts

RecruitingPhase 2
High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients
Immunization; Infection, Transplantation Infection
Active, not recruitingPhase 3
A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried in a Population Aged 10 to 60 Years
Rabies
Active, not recruitingPhase 2
Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer.
Stage IV Colorectal Cancer, Curative Resection
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
Not yet recruiting
The Effect of Health Belief Model-Based HPV Infection and Vaccination Education on University Students' Knowledge and Health Beliefs
Health Belief Model, Nursing Students

All Vaccination trials

Study at a glance

From the registry record, last updated by the sponsor on 7 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: ARISe at UMass Chan: Remote Eye Tracking Study of Vaccine Messaging in Rural Populations
ClinicalTrials.gov ID: NCT07236034
Acronym / sponsor ID: ARISe / STUDY00002075
Conditions: Vaccination, Vaccination Promotion
Keywords: Message perceptions, Vaccination, Immunization
Study type: Interventional
Recruitment status: Recruiting
Enrolment: 700 participants (estimated)
Lead sponsor: University of Massachusetts, WorcesterUniversity, hospital or other
Study start: 1 Dec 2025 (actual)
Primary completion: 30 Sep 2026 (estimated)
Study completion: 30 Dec 2026 (estimated)
First posted: 19 Nov 2025 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Primary purpose: Health services research
Allocation: Randomised
Intervention model: Factorial
Masking: Double blind (participant, investigator)
Number of arms: 14
Model description: Participants will be assigned to one of 14 conditions and view two messages within each.

Arm	Type	Receives
Arm 1: Peer message, 7C Construct 1	Experimental	Behavioral: Exposure to source and message contentThis arm will include messages with a "peer" influence as the source and the construct of "confidence" as the message.
Arm 2: Professional source, 7C Construct 1	Experimental	Behavioral: Exposure to source and message contentThis arm will include messages with a "professional" influencer as the source and the construct of "confidence" as the message.
Arm 3: Peer message, 7C Construct 2	Experimental	Behavioral: Exposure to source and message contentThis arm will include messages with a "peer" influence as the source and the construct of "complacency" as the message.
Arm 4: Professional message, 7C Construct 2	Experimental	Behavioral: Exposure to source and message contentThis arm will include messages with a "professional" influence as the source and the construct of "complacency" as the message.
Arm 5: Peer message, 7C Construct 3	Experimental	Behavioral: Exposure to source and message contentThis arm will include messages with a "peer" influence as the source and the construct of "constraints" as the message.
Arm 6: Professional message, 7C Construct 3	Experimental	Behavioral: Exposure to source and message contentThis arm will include messages with a "professional" influencer as the source and the construct of "constraints" as the message.
Arm 7: Peer message, 7C Construct 4	Experimental	Behavioral: Exposure to source and message contentThis arm will include messages with a "peer" influencer as the source and the construct of "calculation" as the message.
Arm 8: Professional message, 7C Construct 4	Experimental	Behavioral: Exposure to source and message contentThis arm will include messages with a "professional" influencer as the source and the construct of "calculation" as the message.
Arm 9: Peer message, 7C Construct 5	Experimental	Behavioral: Exposure to source and message contentThis arm will include messages with a "peer" influencer as the source and the construct of "collective responsibility" as the message.
Arm 10: Professional message, 7C Construct 5	Experimental	Behavioral: Exposure to source and message contentThis arm will include messages with a "professional" influencer as the source and the construct of "collective responsibility" as the message.
Arm 11: Peer message; 7C Construct 6	Experimental	Behavioral: Exposure to source and message contentThis arm will include messages with a "peer" influencer as the source and the construct of "compliance" as the message.
Arm 12: Professional message, 7C Construct 6	Experimental	Behavioral: Exposure to source and message contentThis arm will include messages with a "professional" influencer as the source and the construct of "compliance" as the message.
Arm 13: Peer message, 7C Construct 7	Experimental	Behavioral: Exposure to source and message contentThis arm will include messages with a "peer" influencer as the source and the construct of "conspiracy" as the message.
Arm 14: Professional message, 7C Construct 7	Experimental	Behavioral: Exposure to source and message contentThis arm will include messages with a "professional" influencer as the source and the construct of "conspiracy" as the message.

Who may qualify

Ages: 18 years and older
Sex: All
Healthy volunteers: Accepted
Age groups: Adult, Older adult

Key inclusion criteria (4 listed)

Age 18+
Living in New England state (CT, MA, ME, NH, VT RI) in a zip code as defined by each individual state's definition of rural
Able to read and write in English
Access to an internet connected computer or laptop with a web-camera

Key exclusion criteria (1 listed)

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Exposure to source and message contentWithin each arm, participants will be exposed to two messages each of which are delivered by the same source (peer or professional) and have message content related to one of the 7C Constructs.	Behavioural	Arm 10: Professional message, 7C Construct 5, Arm 11: Peer message; 7C Construct 6, Arm 12: Professional message, 7C Construct 6, Arm 13: Peer message, 7C Construct 7, Arm 14: Professional message, 7C Construct 7, Arm 1: Peer message, 7C Construct 1, Arm 2: Professional source, 7C Construct 1, Arm 3: Peer message, 7C Construct 2, Arm 4: Professional message, 7C Construct 2, Arm 5: Peer message, 7C Construct 3, Arm 6: Professional message, 7C Construct 3, Arm 7: Peer message, 7C Construct 4, Arm 8: Professional message, 7C Construct 4, Arm 9: Peer message, 7C Construct 5

Primary outcome

Source credibility
Time frame: Immediately after viewing each message
Participants' perception of the credibility of the message source will be assessed using a 7-point Likert scale measured across four items. Participants will be asked to rate the following four items on this scale: To what extent do you believe the source of the message to be… (1=not at all, 7=very much so) 1. Fair 2. Accurate 3. Telling the whole story 4. Trustworthy Unit of measure: Scale score 1-7, mean
Perceived Message Effectiveness
Time frame: Immediately after viewing each message
Perceived message effectiveness will be measured using six items (worth remembering, grabs attention, powerful, informative, meaningful, convincing), each rated on a 7-point Likert scale. The outcome will be the mean of these six ratings for each participant, then averaged by experimental condition. To what extent is… (1=not at all, 7=very much so) 1. The message worth remembering 2. The message grabs attention 3. This message powerful 4. This message informative 5. This message meaningful 6. This message convincing Unit of Measure: Scale score (1-7, mean across items)
Visual attention
Time frame: During message viewing ( immediately post-randomization, prior to completion of post-message survey)
Visual attention, quantified as mean dwell time in milliseconds, will be measured using remote eye-tracking while participants view vaccine promotion messages. Dwell time will be calculated for pre-specified Areas of Interest (AOIs) during the message viewing period. Higher dwell times indicate greater visual attention to the AOIs. Unit of measure: mean dwell time in milliseconds per message
Message reactance
Time frame: Immediately after viewing each message
Reactance will be assessed using four items (irritated, angry, annoyed, aggravated), rated 0 ("None of this feeling") to 4 ("A great deal of this feeling"). The mean reactance score will be calculated for each participant. How much did this message make you feel the following way? Response options: 0 (None of this feeling) to 4 (A great deal of this feeling). 1. Irritated 2. Angry 3. Annoyed 4. Aggravated Unit of Measure: Scale score (0-4, mean across items)
Information sharing intentions
Time frame: Immediately after viewing each message
Description: Assessed with 6 items regarding interpersonal and online sharing, rated 1 (Strongly disagree) to 5 (Strongly agree). The mean score across items will be reported per participant and per condition. Rate with the following statements on a scale from 1 (Strongly disagree) to 5 (Strongly agree). Interpersonal setting 1. I would be willing to share this information with others. 2. I would talk with others about this message. 3. I would point others in a direction where they could read this message. Online setting 4. I would be willing to post a link to this information on my social media. 5. I would like a social media post with this information. 6. I would share a social media post with this information. Unit of Measure: Scale score (1-5, mean across items)

1 secondary outcome

Vaccine perceptions
Time frame: Assessed at baseline (prior to message exposure) and immediately post-intervention (after message exposure)

Results and safety

This study is still under way. Results are not available in the source record yet.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 7 Jul 2026.
Individual participant dataSharing planned: Yes. Per the data management plan, datasets and codebooks will be provided to individual researchers upon reasonable request.

Related trials for Vaccination

RecruitingPhase 2
High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients
Immunization; Infection, Transplantation Infection
Active, not recruitingPhase 3
A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried in a Population Aged 10 to 60 Years
Rabies
Active, not recruitingPhase 2
Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer.
Stage IV Colorectal Cancer, Curative Resection
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
Not yet recruiting
The Effect of Health Belief Model-Based HPV Infection and Vaccination Education on University Students' Knowledge and Health Beliefs
Health Belief Model, Nursing Students

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.

Grace W Ryan, PhD, MPH contact

508-859-0179

grace.ryan1@umassmed.edu

Grace W Ryan, PhD, MPH principal investigator

University of Massachusetts, Worcester

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A study testing Exposure to source and message content in people with Vaccination and Vaccination Promotion, run by University of Massachusetts, Worcester at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 7 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Grace W Ryan, PhD, MPH (508-859-0179, grace.ryan1@umassmed.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Source credibility (time frame: Immediately after viewing each message). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07236034.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jul 2026.